BOSTON, Mass. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways, today announced that Oren Gilad Ph.D, President and Chief Executive